Other IL-6/IL-6R blockades that are FDA-approved or undergoing RCT for autoimmune diseases include clazakizumab, siltuximab, sarilumab, olokizumab, sirukumab, and tofacitnib [127]. Here, IL6R is linked to autoimmune disease.